The glucagon-like peptide-1 (GLP-1) agonist is a distinct category of glucose-lowering drug that has proven effective in decreasing the risk of CV events in people with T2DM who are at heightened risk. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.